| 2024/06/28 17:20:19 | |
|---|---|
| Price | |
| 0.0174 EUR | |
| Difference | -3.33% (-0.00) |
General attributes
| ISIN | BE0974280126 |
| Symbol | BIOS |
| Exchange | Euronext Brussels |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 4 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | 0.0175 EUR (125,000) |
| Ask (Ask size) | 0.0185 EUR (50,000) |
| Open | 0.018 EUR |
| High | 0.0184 EUR |
| Low | 0.0174 EUR |
| Close (prev. day) | 0.018 EUR |
| VWAP | 0.017928 EUR |
| Volume (pcs) | 393,300 |
| Trading volume | 7,051.00 |
| Number of trades | 16 |
| Last size | 51,754 |
Futures and Options
| Related Futures | - |
| Related Options | - |
PDF Downloads
| Company report: BIOSENIC SA |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2024/06/21 |
|
Global Equity Ratings |
|
| 2024/06/14 |
|
Global Equity Ratings |
|
| 2024/05/29 |
|
Global Equity Ratings |
|
| 2024/04/26 |
|
Global Equity Ratings |
|
| 2024/04/03 |
|
Global Equity Ratings |
|
| 2024/06/28 17:20:19 | |
|---|---|
| Price | |
| 0.0174 EUR | |
| Difference | -3.33% (-0.00) |
General attributes
| ISIN | BE0974280126 |
| Symbol | BIOS |
| Exchange | Euronext Brussels |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 4 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | 0.0175 EUR (125,000) |
| Ask (Ask size) | 0.0185 EUR (50,000) |
| Open | 0.018 EUR |
| High | 0.0184 EUR |
| Low | 0.0174 EUR |
| Close (prev. day) | 0.018 EUR |
| VWAP | 0.017928 EUR |
| Volume (pcs) | 393,300 |
| Trading volume | 7,051.00 |
| Number of trades | 16 |
| Last size | 51,754 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -65.65% | -79.02% | -99.31% |
| Perf (abs.) | -0.03 | -0.07 | -2.58 |
| Beta | 0.23 | -0.03 | 0.44 |
| Volatility | 111.19 | 160.19 | 125.26 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 0.0184 EUR (698,618) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 0.0200 EUR (2,673,976) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 0.0231 EUR (1,621,704) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 0.0427 EUR (1,230,503) |
| YTD High | date | 0.0700 EUR (2024/01/02) |
| YTD Low | date | 0.0120 EUR (2024/03/19) |
| 52 Weeks High | date | 0.1890 EUR (2023/09/22) |
| 52 Weeks Low | date | 0.0120 EUR (2024/03/19) |
All listings for BIOSENIC SA
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Stuttgart | 2024/06/28 | 16:29 | 0.0148 EUR | 0.00 | 2 |
| London Stock Exchange | 2021/01/04 | 15:05 | 2.6200 EUR | 0.00 | 1 |
| Frankfurt | 2024/06/28 | 08:04 | 0.01 EUR | 0.00 | 1 |
| Euronext Brussels | 2024/06/28 | 17:20 | 0.0174 EUR | 0.01 | 16 |
| Berlin | 2024/06/28 | 17:55 | 0.0199 EUR | 0.00 | 13 |
Company Logo
Contact Details
| BIOSENIC SA |
| - - |
| Bâtiment H bte 24, Rue Granbonpré 11 - 1435 Mont-Saint-Guibert |
| Telefon: +32-49-309-73-66 |
| Fax: + |
| E-mail: info@biosenic.com |
PDF Downloads
| Company report: BIOSENIC SA | |
Company Profile
BioSenic SA is a biotech company engaged in the development of clinical assets . The company was founded in 2006 and is headquartered in Mont-Saint-Guibert, Belgium. |
Members of Management Board
| Miguel Forte | Chairman of Managing Board |
| Anne Leselbaum | Member of Executive Committee |
| Anne-Sophie Lebrun | Member of Executive Committee |
| Anthony Ting | Member of Executive Committee |
| Stefanos Theoharis | Member of Executive Committee |
Board of directors
| Revital Rattenbach | Member of Supervisory Board |
| Yves Sagot | Member of Supervisory Board |
| Jean Stephenne | Member of Supervisory Board |
| Jean-François Rax | Member of Supervisory Board |
| Jean-Luc Vandebroek | Member of Supervisory Board |
| Véronique Pomi-Schneiter | Member of Supervisory Board |